CERVOMED INC. - COMMON STOCK

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

10 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

27 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Key Senior Leadership Appointments

13 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

12 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

08 Nov 2024 09:55:32 By Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

07 Nov 2024 08:30:00 By Nasdaq GlobeNewswire

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

04 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

29 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

15 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

02 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

26 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Participate in Upcoming Investor Conferences

27 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

22 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

12 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

30 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)

29 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Participate in the Emerging Growth Conference

17 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

11 Jul 2024 08:51:12 By Nasdaq GlobeNewswire

CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes

24 Jun 2024 08:00:00 By Nasdaq GlobeNewswire